ALFA Finder| Management target | Revenue 10.0% FY27 |
|---|
| Revenue growth | 55% total growth, 17% organic base business growth. |
|---|---|
| Margins | EBITDA margins expanded to 33.8% due to merger cost synergies. |
| Demand visibility | Strong chronic demand in India; base business outperforming IPM growth. |
| Management confidence | Balanced; optimistic on synergies but admits Brazil Semaglutide delay miss. |
Growth
Revenue grew 55%, with JB merger contributing significantly. Organic growth led by Brazil (27%) and India (19%).
Outlook
Guided double-digit growth for JB India RX business; net debt/EBITDA stands at 2.07x.
Risks
Semaglutide supply setback in India and loss of first-mover advantage for Semaglutide in Brazil.
Earnings Call Transcript filed with NSE, NSE: TORNTPHARM. Summary written with AI assistance from the document.
Torrent Pharmaceuticals Ltd: key numbers
- Share price
- ₹4,761.00
- Market cap
- ₹1,81,093 Cr
- Revenue (annual)
- ₹13,980 Cr
- Net profit (annual)
- ₹2,163 Cr
- P/E (TTM)
- 85.3×Sector 43.8×
- Promoter holding
- 60.78%-7.53% QoQ
- FII holding
- 17.22%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Torrent Pharmaceuticals Ltd
All →Torrent Pharmaceuticals Debt & Borrowing: ₹100 Cr
Torrent Pharmaceuticals partially redeemed Rs.100 Crore of its unlisted secured NCDs on 09-11-2026, leaving Rs.300 Crore outstanding. This is a debt servicing event, not compliance paperwork.
- Value
- ₹100.0 Cr
Torrent Pharmaceuticals Legal & Regulatory
Torrent Pharma received a ₹3.12 Crore GST penalty order for pre-acquisition JB Chemicals periods. The company will appeal and expects no material impact.
- Value
- ₹3.12 Cr
Torrent Pharmaceuticals Other Announcement
Torrent Pharmaceuticals disclosed that its RTA, KFin Technologies, is moving its corporate office effective December 1, 2026. Investors should update their records with the new address.
Torrent Pharmaceuticals Earnings Call Transcript: Key Takeaways
Revenue grew 51% following the JB Chemicals merger, but underlying business shows integration headwinds.
- Call
- Guides 10% growth
Torrent Pharmaceuticals Debt & Borrowing
Torrent Pharmaceuticals filed its security cover certificate as on 30-Sep-26 for listed NCDs, showing 141% market-value cover. Secured debt covered by the certificate stands at Rs 11,578.42 Crore.
Torrent Pharmaceuticals Q2 FY27 Results: Net Profit ₹534 Cr, Down 9.6% YoY
Torrent Pharmaceuticals Ltd reported revenue from operations of ₹4,979 Cr (+50.8% YoY) and net profit of ₹534 Cr (-9.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹534 Cr · -9.6% YoY